Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zack ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Masimo Corporation, which may affect shareholder rights and corporate governance [1][2]. Group 1: Legal Investigation - The law firm is looking into whether Masimo Corporation's management has acted against the interests of shareholders [1]. - Long-term shareholders may have options for seeking corporate governance reforms and financial recovery [2]. Group 2: Shareholder Involvement - Shareholder participation is emphasized as a means to improve company policies and enhance overall shareholder value [3]. Group 3: Firm's Background - Halper Sadeh LLC has a history of representing investors affected by securities fraud and corporate misconduct, successfully recovering millions for defrauded investors [4].

Masimo Corp (NASDAQ:MASI) on Wednesday hosted its 2025 Investor Day. At the event, Masimo’s management team provided an update on the company’s long-term strategy.Masimo also provided a detailed look at each of its growth pillars and updated its long-range plan through 2028.Management projected a 7%–10% revenue CAGR through 2028, with operating margins reaching about 30%.Also Read: Apple To Reintroduce Blood Oxygen Feature On Select Watches Following Customs RulingThe company is aiming for adjusted EPS of $ ...

Core Insights - Masimo is hosting its 2025 Investor Day to present its strategic vision and operational updates to investors [1][2] - The agenda includes presentations from the executive team focusing on Masimo's strong foundation and plans for expanding its leadership in advanced monitoring [4] Company Overview - Masimo has recently appointed Matthew Brinckman as Senior Vice President of FP&A and Investor Relations, indicating a focus on enhancing investor communication [1] - The company emphasizes the use of non-GAAP measures in its presentations to provide a clearer understanding of its business performance [3]

Summary of Masimo's 2025 Investor Day Company Overview - **Company**: Masimo - **Industry**: Advanced patient monitoring technology - **Key Focus**: Transforming patient care through innovative monitoring solutions, particularly in pulse oximetry and advanced monitoring systems [11][12][13] Core Points and Arguments 1. **Market Leadership**: Masimo is the global leader in patient monitoring, with a significant market share in pediatric and neonatal intensive care environments, attributed to its advanced algorithms for pulse oximetry [9][12] 2. **Patient Impact**: The company aims to make a difference in the lives of over 200 million patients annually across 150 countries [11] 3. **Financial Targets**: Masimo has set long-term financial targets for 2028, aiming for 7%-10% growth, with aspirations for double-digit growth beyond that [17][33] 4. **Product Pipeline**: The company has a multi-year product pipeline, including new algorithms for detecting atrial fibrillation and opioid-induced respiratory depression, expected to launch in 2026 [29][43] 5. **Recurring Revenue**: Masimo boasts an 80% recurring revenue model, supported by a large installed base of over 2.6 million units and a 98% renewal rate on long-term contracts [12][17] 6. **International Expansion**: There is a significant opportunity for growth in international markets, where Masimo currently holds a lower market share compared to the U.S. [24][46] 7. **Clinical Evidence**: The company emphasizes the importance of clinical evidence to validate its technologies, with ongoing studies demonstrating the accuracy of its sensors across different skin tones [60][62] Additional Important Content 1. **Leadership Team**: The leadership team combines long-standing Masimo employees with new talent from other top med tech companies, enhancing the company's innovation and execution capabilities [18][20] 2. **Restructuring and Focus**: The company has undergone restructuring to focus on its core healthcare business, divesting non-core assets like Sound United [13][14] 3. **Intellectual Property**: Masimo is actively defending its intellectual property, recently winning a significant verdict in a case against Apple, which underscores the company's commitment to protecting its innovations [32][33] 4. **Patient Monitoring Opportunities**: The company identifies a $2 billion market opportunity in surveillance monitoring, highlighting the potential for continuous monitoring to prevent costly ICU re-admissions [28][46] 5. **Commercial Strategy**: The commercial team is focused on leveraging the installed base and enhancing sales strategies to drive growth, with a nearly 100% retention rate over the past decade [40][41] This summary encapsulates the key insights and strategic directions discussed during Masimo's 2025 Investor Day, emphasizing the company's commitment to innovation, patient care, and market expansion.

Investor Day DECEMBER 3, 2025 Safe Harbor Statement Forward-Looking Statements This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, statements about our expectations, plans, strategies or prospects. We generally use the words "may," "will," "expect," "believe," "anticipate," "plan," "estimate," "project," "assume," "guide," "target," "forecast," "see," "seek," "can," "should," "could," "would," "intend," "predict," "potential," "strate ...

Core Insights - C10 Labs has appointed Dr. Michael O'Reilly as Chief Medical Advisor to enhance its ability to develop AI-driven healthcare ventures [1][2] - The company aims to bridge the gap between AI research and practical healthcare applications, leveraging Dr. O'Reilly's extensive experience in medical technology [3][4] Company Overview - C10 Labs operates as an Applied AI venture studio and fund, focusing on transforming AI research into commercial ventures in healthcare, energy, and industrial systems [4] - The company is based in Cambridge and New York, utilizing its Applied Venture Science methodology to significantly reduce development timelines from 18-24 months to 90-120 days [4] Leadership and Expertise - Dr. O'Reilly brings a wealth of experience, having previously worked at Apple, where he integrated medical-grade sensors into devices used by over one billion people, and at Masimo, contributing to the $50 billion wearable market [3] - His role at C10 Labs will involve identifying scalable technologies that can impact millions of patients, addressing the challenge of translating research into real-world applications [4] Strategic Initiatives - C10 Labs has been selected to lead NYC's AI Nexus program, which supports over 100 AI ventures through 2029, indicating a strong commitment to fostering innovation in the AI healthcare space [2] - The company emphasizes a hands-on approach to building companies, aiming to ensure that groundbreaking research reaches patients effectively [4]

Core Viewpoint - Masimo (MASI) shows potential for upside based on Wall Street analysts' short-term price targets, with a mean target of $186.14 indicating a 26.6% upside from the current price of $147.03 [1] Price Targets and Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $14.16, suggesting variability among analysts; the lowest estimate is $168.00 (14.3% increase), while the highest is $210.00 (42.8% increase) [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates - Analysts have shown increasing optimism about MASI's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [11] - The Zacks Consensus Estimate for the current year has risen by 3.5% over the past month, with three estimates increasing and no negative revisions [12] Zacks Rank - MASI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of MASI's potential gains, it does provide a useful guide for the direction of price movement [14]

Core Insights - Masimo has won a significant legal victory against Apple, with a jury awarding over $634 million for patent infringement related to the Apple Watch [1][3] - The jury found that Apple infringed all four patents in question, marking one of the largest patent awards in consumer technology in the U.S. [1] Company Overview - Masimo alleged that Apple utilized its patented technology in approximately 43 million Apple Watches without authorization, enabling users to track heart rate while conserving battery life [3] - The trial was supported by DRC, which provided assistance in jury research, selection, and trial strategy [3][4] Legal Team - The trial team for Masimo was led by Brian Horne and included several other attorneys from Knobbe Martens and Sullivan and Cromwell LLP [2]